Age-Related Macular Degeneration Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Age Related Macular Degeneration Market Overview
Age related macular degeneration is one of the leading causes of irreversible vision loss. There is no definitive cause of AMD. However, advanced age, a family history of AMD, systemic conditions such as hypercholesterolemia and obesity, and lifestyle factors such as cigarette smoking have been identified as risk factors.
The number of people with AMD is set to increase in line with the growing aging population in most developed countries. Currently, there is no effective treatment for AMD and GA, which are associated with significant and disabling loss of central vision.
The age related macular degeneration market research report provides an overview of the risk factors, comorbidities, and global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year analytical forecast for total global sales of AMD. The total and forecasted prevalent drug sales of AMD are further segmented by age, sex, and stage in these markets.
Forecast period | 2021-2031 |
Key age segments | 50-59 Years, 60-69 Years, 70-79 Years, and Above 80 Years |
Key sex segments | Men and Women |
Key stage | No AMD, Early AMD, and Intermediate AMD, and Advanced AMD |
Key regions | US, UK, France, Italy, Japan, Germany, Spain |
Key players | Roche, Apellis, Abbvie, Novartis, Genentech, and Outlook Therapeutics |
To gain more information on the age-related macular degeneration market forecast, download a free report sample
Key Age-Related Macular Degeneration Market Drivers
The major driver for the AMD market growth will be the availability of therapies for geographic atrophy (GA), which will increase the number of treatable cases of AMD. Continual pursue of late-stage pipeline therapies for wAMD will be the strongest driver of the market in the 7MM. According to KOLs, Vabysmo’s potential to increase treatment intervals will become a favorable clinical feature in AMD treatment during the forecast period.
Key Age Segments in the Age-Related Macular Degeneration Market
The AMD market can be segmented based on age into 50-59 years, 60-69 years, 70-79 years, and above 80 years.
In 2021, for the 7MM combined, adults ages 60-69 years contributed the highest proportion of the diagnosed prevalent cases of chronic kidney disease followed by the age group 70–79 years.
Age-Related Macular Degeneration Market Analysis by Age
For more age segment insights, download a free report sample
Key Sex Segments in the Age-Related Macular Degeneration Market
The AMD market can be segmented based on sex into men and women.
In the 7MM combined, the number of diagnosed prevalent cases of AMD was higher in women than in men in 2021. However, Italy had the highest gender difference in the number of diagnosed prevalent cases of AMD. Japan had the smallest variation in the number of diagnosed prevalent cases between men and women.
Age-Related Macular Degeneration Market Analysis by Sex
For more sex segment insights, download a free report sample
Key Stages in the Age-Related Macular Degeneration Market
The AMD market can be further divided into four stages: No AMD, Early AMD, and Intermediate AMD, and Advanced AMD. Advanced AMD can be sub categorized into two stages: Late Dry AMD, and Late Wet AMD.
In the 7MM, the highest number of diagnosed prevalent cases of AMD was early AMD. Among the 7MM, Italy had the highest number of diagnosed prevalent cases of AMD in Early AMD stage followed by the US. This difference in stage-specific diagnosed prevalent cases might be driven by the varying stage-specific diagnosis rate in the markets.
Age-Related Macular Degeneration Market Analysis by Stages
For more stage insights, download a free report sample
Key Regions in the Global Sales for Age-Related Macular Degeneration Market
The US is anticipated to experience the fastest growth during the forecast period followed by France, Germany, Italy, Spain, the UK, and Japan.
Age-Related Macular Degeneration Market Analysis by Regions
For more insights on the regions, download a free report sample
Key Players in the Age-Related Macular Degeneration Market
Some of the key players in the AMD market are Roche, Apellis, Abbvie, Novartis, Genentech, and Outlook Therapeutics.
Scope
- Overview of Age-Related Macular Degeneration – including epidemiology, disease etiology, and management.
- Topline AMD drugs market revenue, the annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players, and market outlook for the US, 5U, and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global AMD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global AMD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.
- Track drug sales in the global AMD therapeutics market from 2021 to 2031.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Bayer
Roche
Novartis
AbbVie
RegenxBio
Outlook Therapeutics
Kodiak Sciences
Opthea
Apellis Pharmaceuticals
Alkeus Pharmaceuticals
Iveric Bio
Table of Contents
Table
Figures
Frequently asked questions
-
What was the age-related macular degeneration market size in 2021?
The age-related macular degeneration market size was valued at $7.3 billion in 2021 across the 7MM.
-
What is the age-related macular degeneration market growth rate?
The age-related macular degeneration market is forecast to grow at a CAGR of more than 11% during the forecast period.
-
What are the key age segments in the age-related macular degeneration market?
The age-related macular degeneration market can be segmented based on age into 50-59 years, 60-69 years, 70-79 years, and above 80 years.
-
What are the key sex segments in the age-related macular degeneration market?
The age-related macular degeneration market can be segmented based on sex into men and women.
-
What are the key stages in the age-related macular degeneration market?
The age-related macular degeneration market can be further divided into four stages: No AMD, Early AMD, and Intermediate AMD, and Advanced AMD. Advanced AMD can be sub categorized into two more stages: Dry AMD, and Wet AMD.
-
What are the key regions in the age-related macular degeneration market?
The US is anticipated to experience the fastest growth in the AMD market, during the forecast period, followed by France, Germany, Italy, Spain, the UK, and Japan.
-
Who are the key players in the age-related macular degeneration market?
Some of the key players in the AMD market are Roche, Apellis, Abbvie, Novartis, Genentech, and Outlook Therapeutics.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.